Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSL
Biotech
CSL's largest ph. 3 trial ends in failure for heart attack drug
CSL’s largest trial has ended in failure, as the pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks.
James Waldron
Feb 12, 2024 5:21am
Genexine's anemia drug matches Roche-CSL product in phase 3
Apr 11, 2023 8:05am
CSL links drug to rare disease benefits, plans global filings
Feb 27, 2023 10:15am
uniQure rebounds from FDA setback with $55M Corlieve buy
Jun 22, 2021 3:23pm
FDA lifts clinical hold on uniQure's gene therapy
Apr 26, 2021 8:10am
Plasma therapy backed by CSL, Takeda fails phase 3 COVID-19 test
Apr 5, 2021 7:55am
